Physician profile
Daniel Heusinger
NPI 1710514237
$4,698.09
in general payments reported to CMS, 2019-2025
38 companies · $995 in 2025
The $995 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $879 · 2023: $1,250 · 2024: $1,207 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,452.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $636.87 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.08 | 2021-2025 | Jardiance |
| Amgen INC. | $375.08 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $313.52 | 2021-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Pfizer INC. | $278.93 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $231.19 | 2023-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $220.23 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $206.77 | 2021-2025 | Farxiga, Lokelma |
| Impulse Dynamics (USA) INC. | $186.43 | 2023 | Optimizer |
| Abiomed | $147.91 | 2023-2025 | Impella |
| Novo Nordisk INC | $145.51 | 2022-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $139.25 | 2022-2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $138.66 | 2022-2024 | |
| Edwards Lifesciences Corporation | $133.76 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $111.43 | 2021-2023 | Lifevest |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $97.85 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $95.99 | 2022-2023 | Arcalyst |
| Bridgebio Pharma, INC. | $86.95 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $81.24 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $67.35 | 2024 | Evkeeza |
| Glaxosmithkline, LLC. | $62.29 | 2025 | Trelegy Ellipta, Shingrix |
| Recor Medical INC | $54.30 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boston Scientific Corporation | $52.35 | 2024-2025 | Watchman, Watchman Flx |
| Phathom Pharmaceuticals, INC. | $50.29 | 2024 | Voquezna |
| Lexicon Pharmaceuticals, INC. | $49.44 | 2023-2024 | Inpefa |
| Lundbeck LLC | $49.31 | 2024 | Rexulti |
| Biotronik INC. | $42.18 | 2022 | |
| Amarin Pharma, INC. | $32.53 | 2021-2023 | |
| Abbvie INC. | $29.31 | 2025 | |
| Esperion Therapeutics, INC. | $29.27 | 2023-2024 | Nexletol |
| Lilly USA, LLC | $24.45 | 2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $22.47 | 2025 | Inspire |
| Gilead Sciences, INC. | $22.22 | 2023 | |
| Dexcom, INC. | $20.58 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.46 | 2023 | Rexulti |
| Corcept Therapeutics | $16.36 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $16.26 | 2022 | |
| Tactile Systems Technology INC | $14.02 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Heusinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.